Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nektar Therapeutics (NKTR – Research Report), Enanta Pharmaceuticals (ENTA – Research Report) and Rocket Pharmaceuticals (RCKT – Research Report). Nektar Therapeutics (NKTR) In a report issued on May 17, Daina Graybosch from SVB Securities maintained a Hold rating on Nektar Therapeutics, with a price target of $5.00. The company's shares closed last Wednesday at $3.80, close to its 52-week low of $3.52. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nektar-therapeutics-nktr-enanta-pharmaceuticals-enta-and-rocket-pharmaceuticals-rckt?utm_source=advfn.com&utm_medium=referral
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Rocket Pharmaceuticals Charts.
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Rocket Pharmaceuticals Charts.